Quarterly report pursuant to Section 13 or 15(d)

5. Hybrid Debt Instrument (Details Narrative)

v3.8.0.1
5. Hybrid Debt Instrument (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Change in fair value of derviative liability $ 0 $ 241,298 $ 0 $ 2,146,587  
Loss on issuance of hybrid debt instrument 0 (106,566) 0 (1,690,787)  
Loss on conversion $ 0 0 $ 0 $ (6,187,337)  
Warrants issued     0 212,222  
Interest expense   341,000   $ 690,000  
Pharmsynthez [Member]          
Conversion of debt, shares issued     125,397    
Hybrid Debt Instrument [Member] | Pharmsynthez [Member]          
Conversion of debt, shares issued         1,373,036
Conversion of debt, amount converted         $ 6,500,000
Accrued interest converted         200,000
Loss on conversion         (6,200,000)
Hybrid Debt Instrument [Member] | Asset Purchase Agreement [Member]          
Change in fair value of derviative liability       1,900,000  
Loss on issuance of hybrid debt instrument       $ (1,600,000)  
Additional APA Note [Member] | Pharmsynthez [Member]          
Convertible note face value         $ 500,000
Warrants issued         50,505
Jr. Secured Convertible Promissory Note [Member] | Chief Executive Officer [Member]          
Convertible note face value         $ 369,958
Warrants issued         37,369
Further Notes [Member]          
Warrants issued         50,505
Further Notes [Member] | Note 1 [Member]          
Convertible note face value         $ 178,000
Further Notes [Member] | Note 2 [Member]          
Convertible note face value         $ 322,000
Period Notes [Member]          
Change in fair value of derviative liability   200,000      
Loss on issuance of hybrid debt instrument   $ (100,000)